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Background: Lithium, an effective mood stabilizer for the treatment of bipolar disorders, has been recently suggested
to have a role in neuroprotection during neurodegenerative diseases. The pathogenesis of neurological disorders often
involves the activation of microglia and associated inflammatory processes. Thus, in this study, we aimed to understand
the role of lithium in microglial activation and to elucidate the underlying mechanism(s).
Methods: Primary microglial cells were pretreated with lithium and stimulated with lipopolysaccharide (LPS). The cells were
assessed regarding the responses of pro-inflammatory cytokines, and the associated signaling pathways were evaluated.
Results: Lithium significantly inhibited LPS-induced microglial activation and pro-inflammatory cytokine production.
Further analysis showed that lithium could activate PI3K/Akt signaling. Analyses of the associated signaling
pathways demonstrated that the lithium pretreatment led to the suppression of LPS-induced toll-like receptor 4
(TLR4) expressions via the PI3K/Akt/FoxO1 pathway.
Conclusions: This study demonstrates that lithium can inhibit LPS-induced TLR4 expression and microglial activation
through the PI3K/Akt/FoxO1 signaling pathway. These results suggest that lithium plays an important role in microglial
activation and neuroinflammation-related diseases, which may lead to a new therapeutic strategy for the treatment of
neuroinflammation-related disorders.
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Microglia, the resident immune cells in the brain, play a
pivotal role in the immune surveillance of the central
nervous system (CNS). Consequently, these cells are likely
to play an important role in either the development of
protective immune responses or the progression of
damaging inflammation during CNS disease states
[1-4]. Activated microglia carry out several immune
effector functions typically associated with macrophages.
When subjected to abnormal stimulations, such as* Correspondence: yanning_qian@aliyun.com
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ually become activated and produce numerous inflam-
matory mediators, including tumor necrosis factor-alpha
(TNF-α), prostaglandin E2 (PGE2), interleukin-6 (IL-6), ni-
tric oxide (NO), and reactive oxygen species (ROS). Ac-
cumulation of these pro-inflammatory and cytotoxic
mediators is directly deleterious to the neurons and
subsequently induces further activation of microglia,
resulting in a vicious cycle [5,6]. Thus, inhibition of the
microglial activation and the subsequent inflammatory
process may help identify novel therapeutic strategies
to eliminate the deleterious effects of microglia [3].
TLR4 is a pattern-recognition receptor (PRR) that rec-
ognizes distinct pathogen-associated molecular patterns
(PAMPs), such as LPS, a bacterial cell-wall component, andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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naling adaptors and initiates a series of signaling cascades
that result in the activation of NF-κB and the release of
inflammatory cytokines [8]. Microglial activation can occur
through a toll-like receptor (TLR)-4 mediated pathway.
The presence of functional TLR4 has shown to have dele-
terious effects in neurodegenerative and stroke models and
plays an integral part in microglial signaling in some disease
processes [9].
Lithium, an effective mood stabilizer for the treatment
of bipolar disorder, is a neuroprotective and neurotrophic
agent efficacious in the treatment of several neurode-
generative conditions [10]. On the other hand, numerous
studies have shown that lithium has strong anti-
inflammation effects through suppressing the microglial
activation and attenuating the overexpression of pro-
inflammatory cytokines and chemokines in vivo [11].
However, the detailed mechanisms for the anti-
inflammation effects of lithium on microglia have not
been elucidated. It is unknown whether the anti-inflam-
mation effects of lithium are related to TLR4. In the
present study, we investigate the effects of lithium on
LPS-induced microglial activation and elucidate the
possible mechanisms of its neuroprotective properties.
Materials and methods
Reagents
Dulbecco’s modified Eagle’s medium (DMEM), 0.25%
Trypsin-EDTA solution and fetal calf serum (FCS) were
purchased from Gibco-BRL (Grand Island, NY, USA).
Lithium chloride (LiCl) and LPS (Coli 0111:B4) were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
LY294002, WST-8 dye, RIPA buffer and the BCA kit
were purchased from Beyotime (Shanghai, China). The
specific mouse anti-rat ED8 (anti-CD11b/CD18) mono-
clonal antibody (a marker for complement receptor 3 of
activated microglia) was purchased from AbD Serotec
(Raleigh, NC, USA). Fluoroshield mounting medium
with 4,6-diamidino-2-phenylindole (DAPI) was purchased
from Abcam (Hongkong, China). Rat IL-6 Immunoassay
Kit and Rat TNF-α Immunoassay Kit were obtained from
R&D Systems, Inc. (Minneapolis, MN, USA). Rabbit anti-
TLR4 polyclonal antibody was purchased from Abcam
(Hongkong, China). Specific rabbit monoclonal antibodies
against p-PI3K, p-Akt, p-FoxO1, PI3K, Akt, FoxO1 and
GAPDH, and secondary anti-rabbit and anti-mouse
antibodies were all purchased from Cell Signaling (Boston,
MA, USA). A FITC-conjugated goat anti-mouse IgG
antibody was purchased from Santa Cruz (Santa Cruz
Biotechnology, CA, USA).
Microglia-enriched cultures
Primary rat microglial cells were prepared as described
in a previous protocol, with slight modifications [12].Briefly, whole brains were isolated from Sprague Dawley
(SD) rats at postnatal day one to two. The meninges and
blood vessels were removed completely in cold D-Hank’s
buffered saline. Next, the brains were minced with sterile
scissors and digested with 0.25% Trypsin-EDTA solution
for 10 minutes at 37°C. Trypsinization was stopped by
adding an equal volume of culture medium, which was
high-glucose DMEM containing 10% FBS and penicillin
(100 U/ml)/streptomycin (100 μg/ml). The dissociated
cells were passed through a 100-μm pore mesh, pelleted
at 1,500 rpm for 5 minutes, and resuspended in culture
medium. The cells were seeded on poly-D-lysine pre-
coated cell culture flasks and cultured at 37°C in a hu-
midified atmosphere of 5% CO2/95% air. The medium
was replaced every three to four days after seeding. After
the glial cells formed a confluent monolayer (10 to
14 days), the microglial cells were separated from the
astrocytes by shaking for 5 hours at 150 rpm and seeded
into 6-well culture plates at a density of 105 cells/cm2.
After 24 hours of culture, the cells were starved overnight
and then subjected to treatments. The purity of the micro-
glia was >98% as determined by OX-42 (CD11b)-IR. The




disulfophenyl)-2H-tetrazolium Sodium Salt (WST-8) is
better than 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-
tetrazolium bromide (MTT) for analyzing cell viability,
because it can be reduced to soluble formazan by dehy-
drogenase in the mitochondria and has low cytotoxicity.
The cell viability was measured using the WST-8 dye
according to the manufacturer’s instructions. Briefly, the
microglial cells were seeded into 96-well plates at a density
of 3 × 104 cells/well. Following this treatment, the WST-8
dye was added to each well, then the cells were incubated
at 37°C for 2 hours and the absorbance was determined at
450 nm using a microplate reader.
TNF-α and IL-6 assay
The amount of TNF-α and IL-6 in the culture medium
was measured with a commercial ELISA kit from R&D
Systems.
Western blotting
Cellular proteins were extracted from the primary micro-
glial cells using RIPA buffer. The protein concentration
in the supernatant fluid of the lysate was measured
using a BCA kit. Proteins (50 μg) in the cell extracts were
denatured with sodium dodecyl sulfate (SDS) sample
buffer and separated using 10% SDS-polyacrylamide gel
electrophoresis (PAGE). The proteins were transferred
to a polyvinylidene fluoride (PVDF) microporous
Figure 1 The effects of lithium and lipopolysaccharide (LPS)
on cell viability in primary microglia. The microglial cells were
exposed to different concentrations of LiCl (0.1, 0.3, 1, and 3 mM)
and/or LPS (10 ng/ml) for 24 hours. Cell viability was determined
using a colorimetric method. Each data point represents the
mean ± s.e.m. of at least three separate experiments in which
treatments were performed in quadruplicates.
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then blocked with 5% skim milk for one hour at room
temperature. The membrane was incubated with primary
antibody overnight at 4°C. The following primary anti-
bodies were used: rabbit monoclonal anti-TLR4, −p-PI3K
(p85α), −p-Akt (ser473), −p-FoxO1, −PI3K, −Akt, −FoxO1,
and mouse monoclonal anti-GAPDH (1:1000). After adding
the anti-rabbit or anti-mouse secondary antibody (1:1000)
for 1 hour, the protein bands on the membranes were
detected with an enhanced chemiluminescence kit.
Immunofluorescence
To determine the activation of the microglia, the cells
were fixed with 4% paraformaldehyde for 30 minutes;
non-specific binding was blocked by incubating cells in a
5% BSA and 0.1% Triton X-100 solution for 1 hour at
room temperature. The microglial cells were incubated
with mouse anti-ED8 monoclonal antibody (1:300) in the
blocking solution overnight at 4°C. After three washes
with PBS, the microglial cells were incubated with the
corresponding FITC-conjugated goat anti-mouse IgG
(1:200) for 2 hours at room temperature and the nuclei
were stained with DAPI. Fluorescent images were acquired
using a confocal microscope.
Flow cytometry analysis
The microglial cells were pelleted by centrifugation at
1,500 rpm for 5 minutes, and then fixed in 4% parafor-
maldehyde for 30 minutes. After washing, the cells were
resuspended in PBS. To determine the microglial activation,
the cells were incubated with PE-conjugated mouse anti-rat
ED8 monoclonal antibody or isotype control (1:200) at
37°C for 1 hour, resuspended in PBS and analyzed on a
FACS Calibur flow cytometer using CellQuest software
(BD Biosciences, San Jose, CA, USA).
RNAi transfection
The primary microglial cells were transfected under serum-
free conditions with TLR4 (100 nM), FoxO1 (100 nM)
or control siRNA sequences using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA), according to the man-
ufacturer’s instructions. Eight hours later, the medium
was replaced with regular culture medium containing
serum, and the incubation was continued for 48 hours
at 37°C before the assays were performed.
Statistical analysis
All experimental results were from at least three separate
experiments. The data were represented as the mean ±
s.e.m. The significance of the difference between the
control and samples treated with various compounds
was determined by one-way ANOVA followed by the
post-hoc least significant difference test. The differences
were considered significant at P <0.05.Results
Effects of lithium and lipopolysaccharide (LPS) on cell
viability in microglia
WST-8 assay was used to evaluate the toxic effects of
lithium and/or LPS on microglia. The microglial cells
were incubated with lithium (0.1, 0.3, 1.0 and 3.0 mM)
and/or LPS (10 ng/ml) for 24 hours, and then cell viability
was detected by WST-8 assay. Our results indicate that
lithium and 10 ng/ml LPS exert no obvious toxic effects
on microglia (Figure 1).
Lithium inhibits lipopolysaccharide (LPS)-induced
microglial activation
Activated microglial cells were detected with monoclonal
ED8, which recognizes complement receptor 3 (CR3). The
microglial cells were pretreated with various concentra-
tions of lithium (0.3, 1.0 and 3.0 mM) for 30 minutes and
then stimulated with LPS (10 ng/ml) for 24 hours. Flow
cytometric analysis showed that approximately 47.0%
microglial cells were activated by LPS, and the number
was decreased to 39.3%, 32.9%, and 14.9% when cells were
pre-incubated with lithium at 0.3, 1 and 3 mM, respect-
ively (Figure 2a and b). Meanwhile, lithium remarkably
inhibited LPS-induced ED8-positive expression (in green)
upregulation (Figure 2c). These results suggest that lith-
ium can inhibit LPS-induced microglial activation.
Lithium downregulates the production of IL-6 and TNF-α
by lipopolysaccharide-stimulated microglia
Microglia-mediated neuroinflammation occurs primarily
due to the excessive pro-inflammatory mediators and
cytotoxic factors released from activated microglia and
their downstream signaling cascades. The levels of pro-
Figure 2 Lithium inhibits lipopolysaccharide (LPS)-induced microglial activation. Primary microglial cells were pretreated with LiCl at 0.3,
1 and 3 mM for 30 minutes and then stimulated with LPS at 10 ng/ml for 24 hours. (a) and (b) For flow cytometric analysis, the cells were incubated
with PE-conjugated ED8 antibody at 37°C for 1 hour. **P <0.01 versus the response to medium alone. #P <0.05, ##P <0.01 versus LPS treatment
groups. The data are presented as the mean ± s.e.m. of three independent experiments. (c) The cells were stained with ED8 antibody and upregulated
ED8-immunopositive expression (green) on the activated microglia was observed using confocal scanning. The blue staining represents DAPI. Scale
bar 50 μm.
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study. As shown in Figure 3a and b, following the incuba-
tion with LPS at 10 ng/ml for 24 hours, the production of
IL-6 and TNF-α from primary microglial cells significantlyincreased by up to approximately 3359% and 1512%
that of the control, respectively. Pre-incubation with
various concentrations of lithium (0.3, 1.0 and 3.0 mM)
for 30 minutes partially abolished LPS-induced IL-6 and
Figure 3 Lithium downregulates the production of IL-6 and
TNF-α from lipopolysaccharide (LPS)-stimulated microglia.
(a) and (b) Quantification of IL-6 and TNF-α production in media.
The primary microglial cells were pretreated with LiCl at 0.3, 1 and
3 mM for 30 minutes and then stimulated with LPS at 10 ng/ml for
24 hours. **P <0.01 versus the response to medium alone. #P <0.05,
##P <0.01 versus the LPS treatment groups. The data are presented
as the mean ± s.e.m. of three independent experiments.
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that lithium can downregulate LPS-induced production of
inflammatory factors.TLR4 regulates microglial activation
After microglial cells were transfected with TLR4 siRNA
for 48 hours, the TLR4-specific siRNA could downregu-
late 70% of the total TLR4 protein (Figure 4a). The micro-
glial cells were incubated with LPS for 24 hours. As
shown in Figure 4b, the TLR4-specific siRNA could inhibit
IL-6 and TNF-α release from the LPS-stimulated micro-
glia. Similarly, the ED8-positive expression (in green) was
significantly downregulated by the TLR4-specific siRNA
(Figure 4c). These results indicate that TLR4 can regulate
microglial activation and inflammatory response.Effects of lithium on PI3K/Akt/FoxO1 activation and TLR4
expression in microglia
Phosphatidylinositol 3-kinase (PI3K)/Akt is the predom-
inant signaling transduction pathway responsible for the
synthesis and production of pro-inflammation mediators
and can regulate the expression of TLR4 [13,14]. Our re-
sults suggested that lithium could inhibit IL-6 and TNF-α
release from the LPS-induced microglia. We investigated
whether lithium could affect PI3K/Akt phosphorylation
and TLR4 expression in microglia.
Treatment with lithium led to a rapid phosphorylation
of PI3K, Akt and FoxO1, indicative of PI3K/Akt activation
and FoxO1 inhibition, with the peak levels of phosphor-
PI3K, phosphor-Akt and phosphor-FoxO1 occurring at
2 h (Figure 5a and b). However, lithium alone had no
effect on the expression of TLR4 in our study (Figure 5c
and d). These results indicate that lithium can active the
PI3K/Akt/FoxO1 signaling pathways in microglia.
Lithium reduces lipopolysaccharide (LPS)-induced TLR4
expression and inflammatory responses by activating
PI3K/Akt signaling
Our data showed that lithium could suppress LPS-induced
microglial activation and activate PI3K/Akt signaling. It is
known that the PI3K/Akt pathway plays a role in regulating
the expression of TLR4 [14]. Thus, we next tested the
hypothesis that lithium may regulate TLR4 expression
through the PI3K/Akt pathway in LPS-induced microglia.
The microglial cells were pretreated with lithium for
30 minutes, followed by the addition of LPS. It indicated
that lithium substantially inhibited the TLR4 expression
induced by LPS (Figure 6a and b). To investigate the role
of PI3K/Akt signaling in the inhibition of TLR4 expression
by lithium, we used a PI3K inhibitor (LY294002) to
block the PI3K/AKT pathway. The inhibition of PI3K
abolished the effect of lithium on the TLR4 expression
in LPS-induced microglia (Figure 6a and b). Consist-
ently, the IL-6 and TNF-α production were markedly
decreased by lithium, and this effect was abolished by
the PI3K inhibitor LY294002 (Figure 6c). As shown in
Figure 6a and b, we found that the Akt phosphorylation
induced by lithium was abolished by LY294002, suggesting
that the lithium-induced Akt activation is mediated by
PI3K signaling. Additionally, we found that the inhibition
of PI3K could enhance LPS-stimulated TLR4 expression
and the production of IL-6 and TNF-α in microglia
(Figure 6a, b and c). These results suggest that the
PI3K/AKT pathway has a role in LPS-induced micro-
glial activation, and that lithium reduces LPS-induced
TLR4 expression and inflammatory responses by acti-
vating PI3K/Akt signaling. We also found that lithium
could upregulate phosphorylated FoxO1 expression by
activating PI3K/Akt signaling in LPS-induced microglial
activation (Figure 6a and b).
Figure 4 TLR4 regulates microglial activation. Primary microglial cells were transfected with TLR4 siRNA (100 nM) or control (siControl) for
48 hours and then stimulated with lipopolysaccharide (LPS) (10 ng/ml) for 24 hours. (a) Suppression of TLR4 expression by TLR4 siRNA.
(b) Quantification of IL-6 and TNF-α production in media, **P <0.01 versus the response to medium alone. ##P <0.01 versus LPS treatment groups.
The data are presented as the mean ± s.e.m. of three independent experiments. (c) The cells were stained with ED8 antibody and upregulated
ED8-immunopositive expression (green) on activated microglia was observed using confocal. The blue staining represents DAPI. Scale bar 50 μm.
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The transcriptional activity of FoxO1 is inhibited through
its phosphorylation by PI3K/Akt, resulting in its nuclear
exclusion and inhibition of target gene expression. To test
whether FoxO1 is involved in the effect of lithium on
TLR4 expression, the microglial cells were transfected
with FoxO1-specific siRNA for 48 hours and then co-
stimulated with LiCl and LPS. Our results demonstrated
that the transfection of FoxO1-specific siRNA significantly
decreased the expression of FoxO1 in the microglia
(Figure 7a). As shown in Figure 7b, c and d, the trans-
fection of FoxO1-specific siRNA enhanced the effects
of lithium on LPS-induced TLR4 expression, PI3K/
AKT phosphorylation and the production of IL-6 and
TNF-α. In contrast, the TLR4 protein level induced by
LPS was abolished by the FoxO1-specific siRNA (Figure 7b
and c). Similarly, LPS-induced IL-6 and TNF-α produc-
tion was also abolished by the FoxO1-specific siRNA
(Figure 7d). These results indicate that FoxO1 is involved
in the inhibitor effect of lithium on LPS-simulated TLR4expression and microglial activation and FoxO1 maintains
LPS-triggered TLR4-mediated inflammation signaling.
Discussion
The anti-inflammatory effects of lithium on neuroin-
flammation have been widely confirmed and have been
associated with the inhibition of microglial activation
[11,15]. However, little is known about the mechanism
of lithium-mediated inhibition of microglial activation.
In this paper, we demonstrate that lithium inhibits LPS-
induced upregulation of TLR4 in microglia by activating
the PI3K/Akt/FoxO1 signaling pathway.
Microglial activation has been demonstrated to be an
early sign that often precedes and triggers neuronal death
in chronic neurodegenerative diseases [3,5,16]. Therefore,
the inhibition of microglial activation and subsequent neu-
roinflammation may offer prospective clinical therapeutic
benefits for neuroinflammation-related neurodegenerative
disorders. Lithium is an established drug used in the
treatment of bipolar disorder. Recent in vivo studies
Figure 6 Lithium reduces lipopolysaccharide (LPS)-induced TLR4 expression and inflammatory responses by activating PI3K/Akt
signaling. (a) Western blotting analysis of TLR4, p-PI3K, p-Akt and p-FoxO1 expression in LPS-stimulated primary microglia after treatment with
PI3K inhibitor LY294002 (10 μM) and/or LiCl (3 mM). The levels of p-PI3K, p-Akt, p-FoxO1 and TLR4 (b) were quantified and normalized with the
total PI3K, Akt, FoxO1 or GAPDH levels, respectively. Each value was then expressed relative to the one treated with medium, which was set as 1.
(c) ELISA-based IL-6/TNF-α levels in cell culture supernatants. *P <0.05, **P <0.01 versus the response to medium alone. #P <0.05, ##P <0.01,
ΔΔP <0.01 versus LPS treatment groups. &&P <0.01 versus LiCl + LPS treatment groups. The data are presented as the mean ± s.e.m. of three
independent experiments.
Figure 5 Effects of lithium on PI3K/Akt activation and TLR4 expression in microglia. (a) Representative images of western blot for the
activation of PI3K, Akt, FoxO1. The primary microglial cells were incubated with LiCl (3 mM) for 15 minutes; 30 minutes; and 1, 2, 4, 8, 12, and
24 hours. (c) Effects of lithium on TLR4 expression. The cells were incubated with various concentrations of LiCl for 24 hours. The levels of p-PI3K,
p-Akt, p-FoxO1 (b) and TLR4 (d) were quantified and normalized with their respective total PI3K, Akt, FoxO1 or GAPDH levels. Each value was then
expressed relative to the one treated with medium, which was set as 1. *P <0.05, **P <0.01 versus the response to medium alone. The data are
presented as the mean ± s.e.m. of three independent experiments.
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Figure 7 Role of FoxO1 in lithium regulates TLR4 signaling. (a) Suppression of FoxO1 expression by FoxO1 siRNA. The primary microglial
cells were transfected with TLR4 siRNA (100 nM) or control (siControl) for 48 hours. (b) Western blotting analysis of the expression of TLR4, p-PI3K
and p-Akt in lipopolysaccharide (LPS)-stimulated primary microglia after transfection with FoxO1 siRNA (100 nM) and/or LiCl (3 mM). The levels of
p-PI3K, p-Akt and TLR4 (c) were quantified and normalized with their respective total PI3K, Akt or GAPDH levels. Each value was then expressed
relative to the one treated with medium, which was set as 1. (d) ELISA-based IL-6/TNF-α levels in cell culture supernatants. **P <0.01 versus the
response to medium alone. ##P <0.01, ΔΔP <0.01 versus LPS treatment groups. &&P <0.01 versus LiCl + LPS treatment groups. The data are presented as
the mean ± s.e.m. of three independent experiments.
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ties [11,15], reducing inflammatory response and microglial
activation. However, the effects of lithium on microglial
activation in vitro are not completely elucidated. In this
study, we demonstrated that lithium could not only inhibit
LPS-stimulated activation of primary microglia, but also re-
duce IL-6 and TNF-α production from activated microglia.
TLR4, as the receptor of LPS, serves as the primary
mediator of innate immune responses to pathogens by
activating a cascade of pro-inflammatory events [17].
The activation of TLR4 by LPS triggers signaling via
downstream signaling factors such as adaptor myeloid
differentiation protein 88 (MyD88), leading to the activa-
tion of nuclear factor-κB (NF-κB) and ultimately inducing
the expression of inflammation-related genes [18]. Thus,
the inhibition of TLR4 can inactivate pro-inflammatory
downstream signaling pathways by suppressing differential
target gene expression and cellular responses. It is indi-
cated that inhibiting TLR4 expression can suppress LPS-
stimulated production of IL-β and TNF-α in the BV-2microglial cell line [19]. The results presented in our study
also demonstrate that the inhibition of TLR4 expression
suppresses LPS-induced microglial activation and reduces
cytokine production. In addition, we found that lithium
inhibited the expression of TLR4, which may be involved
in the inhibitory effect of lithium on microglial activation.
PI3K/Akt, which is activated downstream of TLR4
[13,20], is an important regulator of inflammation and is
reported to play an important role in negatively regulat-
ing LPS-induced IL-6 and TNF-α production from bone
marrow macrophages (BMM) [14]. Several recent studies
have showed that the neuroprotective effects of lithium is
achieved by activating the PI3K/Akt pathway [21,22]. In
cultured rat cerebellar granule cells (CGCs), lithium treat-
ment rapidly normalized glutamate-induced inactivation
of Akt by activating PI3K and subsequently increasing the
phosphorylation of Akt at its Ser473 residue [21]. It is well
established that lithium elicits neuroprotection, in part,
through its ability to inhibit GSK-3β [23-25]; however, the
PI3K-specific inhibitor LY294002 reversed the effects of
Figure 8 Schematic illustration of lithium-mediated suppression
of neuroinflammation. FoxO1 maintains lipopolysaccharide
(LPS)-triggered TLR4-mediated inflammation signaling. LPS inactivates
microglial FoxO1 by inducing PI3K/Akt signaling, which triggers the
phosphorylation and nuclear exclusion of FoxO1. The TLR4-PI3K/Akt-FoxO1
axis provides a self-limiting mechanism by which macrophages avoid
inappropriate overactivation of inflammation after initiation of the
inflammatory response. Lithium, an activator of PI3K/Akt signaling,
enhances the self-limiting mechanism and inhibits the activation of
microglia. TLR4, toll-like receptor 4;➞, lead to/activate; ⊣, inhibit.
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that lithium could activate the PI3K/Akt pathway in a
time-dependent manner in primary microglia. We add-
itionally found that lithium inhibited the expression of
TLR4 and cytokine production in LPS-induced microglia
by activating the PI3K/Akt pathway, which was abolished
by LY294002. The observations suggest that PI3K/Akt is a
key signaling effector, which controls LPS-induced micro-
glial activation. These results are in accordance with the
fact that PI3K/Akt is a potent suppressor of inflammatory
response in monocytes/macrophages [26,27].
FoxO1, also known as FKHR, along with two other
mammalian isoforms (FoxO3 and FoxO4), constitute the
O class of the forkhead transcription factor family (FoxO),
a large array of transcription factors characterized by the
presence of a conserved 110-amino acid winged helix
DNA-binding domain (DBD) [28]. FoxO1 has important
functions in a wide range of cellular processes, such as
DNA repair, cell cycle control, stress resistance, apoptosis
and metabolism [29-31]. Moreover, the transcriptional
activity of FoxO1 is inhibited through phosphorylation
by PI3K/Akt, resulting in its nuclear exclusion and inhib-
ition of the target gene expression [29,32]. Mounting
studies have showed that FoxO1 plays a key role in
hematopoietic and immune cells [33-36]. FoxO1 can
stimulate the expression of IL-6, TNF-α and IL-1β in
LPS-induced macrophages by upregulating the TLR4
gene expression [37]. However, the function of FoxO1
in neuroinflammation is unclear. In the present study, we
found that lithium could upregulate the phosphorylation
of FoxO1 by activating PI3K/Akt signaling in LPS-
induced microglial activation (Figure 6a and b), indicating
that lithium can inhibit the transcriptional activity of
FoxO1. To investigate the role of FoxO1 in microglia,
we further used FoxO1-specific siRNA to inhibit the
expression of FoxO1. We found that the inhibition of
the expression of FoxO1 abolished LPS-stimulated TLR4
expression and inflammatory response in microglia, which
was even more effective than lithium pretreated microglia.
It is suggested that FoxO1, as a transcription factor, can
regulate the TLR4 gene expression in microglia, which is
in accordance with the fact that FoxO1 is a transcriptional
regulator of TLR4 and its pro-inflammatory pathway in
macrophages [37]. Being downstream of TLR4, the activa-
tion of PI3K/Akt was downregulated with the inhibition
of TLR4 expression.
PI3K/Akt, as the downstream of TLR4, its phosphorylation
is dependent on the TLR4 activation in LPS-stimulated
microglia. Thus, TLR4 is essential for LPS-induced PI3K/
Akt activation [38,39]. In Figure 6, as TLR4 was upregu-
lated by LPS, PI3K/Akt was subsequently phosphorylated.
PI3K/Akt-mediated phosphorylation of FoxO1 with
subsequent nuclear export and degradation is its most
important functional regulatory mechanism. Consistentwith these findings, we observed that LPS-induced
TLR4 activation led to the rapid phosphorylation of
FoxO1 (Figure 6a and b). Hence, while FoxO1 maintains
LPS-triggered TLR4-mediated inflammation signaling,
the TLR4-PI3K/Akt pathway may in turn inactivate
FoxO1 transactivation and limit the inflammatory re-
sponse. This self-limiting feedback mechanism plays a
role in prevention of inflammatory response hyperacti-
vation, which could be enhanced by lithium.
Therefore, we depict putative molecular mechanisms by
which lithium may regulate LPS-induced TLR4 expression
in microglia (Figure 8). Lithium activates PI3K/Akt sig-
naling, which triggers the phosphorylation of FoxO1.
FoxO1, as a transcription factor, can activate TLR4 gene
expression. However, once phosphorylated, the phos-
phorylated FoxO1 proteins are exported from the nucleus
and become sequestered in the cytoplasm, which results
in the downregulation of TLR4 gene expression.
Conclusions
In conclusion, this study demonstrates that lithium can
inhibit LPS-induced TLR4 expression and microglial
activation through the PI3K/Akt/FoxO1 signaling pathway.
These results suggest that lithium plays an important role
Dong et al. Journal of Neuroinflammation 2014, 11:140 Page 10 of 11
http://www.jneuroinflammation.com/content/11/1/140in microglial activation and neuroinflammation-related dis-
eases, which may provide a new therapeutic strategy for the
treatment of neuroinflammation-related disorders.
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